GET DAILY SIGNALSPurple Biotech Ltd. (PPBT): Charting a Potential +56% Climb to $2.00
Key Takeaways
- The central target of $2.00 is not an analyst consensus: only one analyst currently covers PPBT, so the target is drawn from public discussion and a technical-recovery milestone, not a published price-target average.
- The latest verified price sits near $1.28, meaning the stock would need to rise roughly 56% to reach $2.00 — a substantial move for a micro-cap clinical-stage biotech.
- For context, the single available analyst price target is $17 from H.C. Wainwright (analyst Emily Bodnar, Buy rating), lowered from $30 in August 2026 — a figure implying well over 1,000% upside that reflects one firm's discounted cash flow model, not a consensus.
- The strongest supporting factor is the CAPTN-3 preclinical platform, led by IM1240, which was selected for an oral presentation at the EORTC-NCI-AACR symposium in November 2026.
- The biggest risks are a low cash position, ongoing share dilution through at-the-market offerings, and Nasdaq minimum bid price compliance concerns.
- For more detail on the company, visit the Major News and Today's Price Move pages, the Forecast page, and the Earnings page.
- Explore Trending AI Robots to see how AI-driven trading strategies are screening stocks and ETFs like PPBT in real time.
Analyst Views and the Single Price Target
Purple Biotech Ltd. (PPBT) is an Israeli clinical-stage immuno-oncology company whose American Depositary Receipts trade on the Nasdaq Capital Market. With only one sell-side firm publishing a target, the stock lacks a meaningful consensus, so the discussion here centers on a fallback level based on technical considerations and market commentary. The lone view comes from H.C. Wainwright analyst Emily Bodnar, who holds a Buy rating. In August 2026 the firm cut its target to $17 from $30, pointing to a thin cash position and higher operating expenses. That $17 figure represents one discounted cash flow estimate and implies more than 1,200% upside; it should not be viewed as a broad consensus.
Current Price and the Path to $2.00
Shares recently changed hands near $1.28, close to the lower end of a 52-week range stretching from roughly $0.91 to $8.90. A move to $2.00 would require a gain of about 56%, a sizable advance for this micro-cap name. PPBT has been sharply de-rated in 2026 amid heavy dilution, a declining cash balance, and a leadership change. The most plausible route to the target would involve balance-sheet stabilization, constructive reception of CAPTN-3 preclinical data, and a broader improvement in sentiment toward small-cap biotech.
Positive Factors That Could Support the Move
The clearest catalyst remains the CAPTN-3 platform of masked tri-specific antibodies that engage both T cells and NK cells in the tumor microenvironment. Lead candidate IM1240 earned an oral presentation slot at the 38th EORTC-NCI-AACR Symposium in November 2026, an event that has drawn attention to the program in the past. A first-in-human study is slated for 2027. The company has reported roughly $6.1 million in cash expected to last into mid-2027, and interim CEO Isaac Israel has taken the helm. Regaining Nasdaq compliance and completing a financing that limits dilution would also help sentiment. When reviewing comparable names I sometimes cross-check with Tickeron’s AI Screener to see how the stock stacks up within the sector.
Risks That Could Keep the Target Out of Reach
Purple Biotech is still a pre-revenue, unprofitable micro-cap with a market capitalization around $10.5 million and a large share count after at-the-market sales. Continued equity issuance may exert ongoing downward pressure, making a sustained 56% recovery harder to achieve. The company has noted the risk of Nasdaq delisting if the ADSs fall below minimum bid-price requirements, which could reduce liquidity and institutional interest. Preclinical results may not translate into clinical success, and the coming year holds no human efficacy data. Execution around the management transition and broader weakness in small-cap biotechnology add further headwinds.
Technical Levels Worth Watching
The technical picture remains difficult. The $0.91 52-week low serves as key support, while the $1.00 psychological level is notable because it sits near Nasdaq’s minimum bid-price threshold. On the upside, $2.00 is a round-number milestone, yet shares would first need to clear $1.50 before any sustained advance. The $8.90 52-week high remains distant and highlights how far the stock has fallen. I also checked recent patterns with Tickeron’s AI Real Time Patterns for additional context on short-term behavior.
Time Horizon and Items to Monitor
Analyst targets generally reflect a roughly 12-month horizon, though the single-coverage situation limits the signal. Investors should watch the IM1240 oral presentation, any preclinical updates on IM1240 and IM1305, third-quarter results (expected mid-November 2026 with a consensus loss near $2.88 per share), cash-runway commentary, financing or ATM activity, Nasdaq compliance status, and leadership developments. The $2.00 level implies no definitive forecast.
Final Assessment
The $2.00 target functions as a technical-recovery benchmark rather than an analyst consensus, given that only one firm publishes a price objective for PPBT. With shares near $1.28, reaching that level would require a gain of roughly 56%. The bull case rests on the CAPTN-3 platform, the IM1240 presentation, and the planned 2027 first-in-human study, while the bear case centers on limited cash, ongoing dilution, Nasdaq compliance risk, and a lengthy wait for clinical data. Focus next on the symposium presentation, quarterly results, financing moves, and cash updates, keeping in mind that the stock is highly speculative and no particular outcome is assured.
AI Tools in My Research Process
In my own work I regularly consult Tickeron’s AI Daily Buy/Sell Signals to monitor price action across volatile micro-cap names like PPBT. The platform applies artificial intelligence to thousands of stocks and ETFs, surfacing Buy, Sell, or Hold signals based on technical shifts and market conditions. It helps place daily moves into a broader, data-driven framework without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT's Stochastic Oscillator is remaining in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PPBT's RSI Indicator exited the oversold zone, 45 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
Advertisement